Online first
Original article
Published online: 2024-04-25

open access

Page views 68
Article views/downloads 101
Get Citation

Connect on Social Media

Connect on Social Media

Tolvaptan in autosomal dominant polycystic kidney disease – a real-life experience

Julia Borowiecka1, Leszek Pączek2, Mariusz Niemczyk1

Abstract

Background. Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic disease of the kidney, leading to end-stage kidney disease (ESKD) in a large proportion of affected individuals. The only approved therapy to slow the progression of chronic kidney disease (CKD) secondary to ADPKD is tolvaptan. The aim of our analysis was to present the experience of our center with tolvaptan used for ADPKD. Methods. Retrospective analysis of single center data. The study group consisted of 13 patients who started treatment with tolvaptan. The control group consisted of 13 patients who refused to be treated with tolvaptan. Results. In the study group, 2 patients (15%) discontinued tolvaptan due to the side effects. The intention to treat (ITT) analysis showed that among both groups progression of CKD occurred during the observation period. No statistically significant difference in the median change of eGFR was noticed between the study and the control group. Moreover, no statistically significant difference in the median change of eGFR was noticed between pre-study period and the observation period both in the study group and in the control group. Conclusions. According to our results, tolvaptan is not effective in slowing the progression of CKD in patients with ADPKD in real-life settings. Further observations are needed to confirm our results.

Article available in PDF format

View PDF Download PDF file

References

  1. Rangan G, Alexander S, Campbell K, et al. KHA‐CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology. 2016; 21(8): 705–716.
  2. Chapman AB, Devuyst O, Eckardt KU, et al. Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015; 88(1): 17–27.
  3. Reiterová J, Tesař V. Autosomal dominant polycystic kidney disease: from pathophysiology of cystogenesis to advances in the treatment. Int J Mol Sci. 2022; 23(6).
  4. Torres VE, Higashihara E, Devuyst O, et al. TEMPO 3:4 Trial Investigators. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial. Clin J Am Soc Nephrol. 2016; 11(5): 803–811.
  5. Torres VE, Chapman AB, Devuyst O, et al. REPRISE Trial Investigators. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017; 377(20): 1930–1942.
  6. Edwards ME, Chebib FT, Irazabal MV, et al. Long-Term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018; 13(8): 1153–1161.
  7. Müller RU, Messchendorp AL, Birn H, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant. 2022; 37(5): 825–839.
  8. Obwieszczenie Ministra Zdrowia z dnia 21 października 2021 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 listopada 2021 r. https://www.gov.pl/web/zdrowie/obwieszczenie-ministra-zdrowia-z-dnia-21-pazdziernika-2021-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-listopada-2021-r (19.04.2024).
  9. Van Noorden R. Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed? Nature. 2023; 619(7970): 454–458.
  10. Gheorghiade M, Konstam MA, Burnett JC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007; 297(12): 1332–1343.
  11. Register. In: Rauscher T. ed. Band IV Europäisches Zivilprozess- und Kollisionsrecht EuZPR/EuIPR, . Verlag Dr. Otto Schmidt, Köln 2015: 1319–1336.
  12. Li X, Li W, Li Y, et al. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis. Nefrologia (Engl Ed). 2023; 43(6): 731–741.
  13. Cirella I, di Vico V, Rigato M, et al. [Tolvaptan in ADPKD patients at the University of Padova Nephrology Unit: impact on quality of life, efficacy and safety]. G Ital Nefrol. 2022; 39(3).
  14. Calvaruso L, Yau K, Akbari P, et al. Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort. Sci Rep. 2023; 13(1): 22257.
  15. Chong J, Harris T, Ong ACM. Regional variation in tolvaptan prescribing across England: national data and retrospective evaluation from an expert centre. Clin Kidney J. 2023; 16(1): 61–68.
  16. Gkekas E, Tang TY, Green A, et al. Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan. Front Nephrol. 2022; 2: 984165.
  17. Masuda H, Shimizu N, Sekine K, et al. Efficacy and safety of tolvaptan for patients with autosomal dominant polycystic kidney disease in real-world practice: A Single Institution Retrospective Study. In Vivo. 2023; 37(2): 801–805.
  18. Gkika V, Louka M, Tsagkatakis M, et al. The efficacy, the treatment response and the aquaretic effects of a three-year tolvaptan regimen in polycystic kidney disease patients. Clin Pract. 2023; 13(5): 1035–1042.
  19. PKD Foundation Variant Database. https://pkdb.mayo.edu/variants (19.04.2024).
  20. Akihisa T, Kataoka H, Makabe S, et al. Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease. Clin Exp Nephrol. 2022; 26(6): 540–551.